Companies / South Africa
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
MSD Grants Two More Efavirenz Licences
June 2008 | Company News AlertSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
Merck Sharpe & Dohme (MSD), the international subsidiary of US-based Merck & Co has granted a further two licences for generic versions of its antiretroviral (ARV) Stocrin (efavirenz) in South Africa. BMI views the timing of the announcement as an attempt to deflect criticism of alleged anticompetitive practices by MSD ahead of the awarding of contracts under the new HIV/AIDS drug tender, which should be decided in a matter of